Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
481.00    0.00 (0.00%)
Bid:
483.20
Ask:
484.40
Spread: 1.20 (0.248%)
Market Cap: £1.30b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Directorate Change

24 Jun 2014 07:00

RNS Number : 3280K
Chemring Group PLC
24 June 2014
 



 FOR IMMEDIATE RELEASE 24 JUNE 2014

 

CHEMRING GROUP PLC

 

Directorate change

 

Michael Flowers appointed Group Chief Executive

 

Chemring Group PLC ("Chemring" or "the Group") announces that Michael Flowers has been appointed Group Chief Executive with immediate effect. Michael joined Chemring in 2006 and prior to today's appointment was Group Director, Countermeasures and a member of Chemring's Executive Committee.

 

Michael Flowers has spent 13 years in senior management positions within the defence industry. He previously served as an officer in the Australian Army for 22 years and was a graduate of the Australian Command and Staff College and the British Royal Military College of Science. After leaving the army, he was a senior manager at BAE Systems from 2001 to 2006, in programme and project management roles.

 

From 2006, he was Managing Director, Chemring Australia, where he established a state of the art countermeasures manufacturing facility and delivered substantial growth in the defence portfolio. In 2013, he was appointed Group Director, Munitions, with responsibility for Chemring's European munitions business. Michael led the successful sale of the European munitions business following the 2013 strategic review, working closely with Chemring's Board and advisers to negotiate and complete the disposal in May 2014.

 

Mark Papworth has stepped down from the Board of Chemring with immediate effect. 

 

Peter Hickson, Chairman of Chemring, said:

 

"Michael Flowers has a proven track record, both within the international defence industry and within Chemring, where he led our Australian business through a successful period of growth and, more recently, managed the complex disposal process of the European munitions business. Michael is extremely knowledgeable about our markets and is well qualified to lead Chemring as we capitalise on our world leading technologies in Countermeasures, Sensors & Electronics and Energetic Systems.

 

Much has been achieved during Mark Papworth's tenure, including a significant reorganisation and refocusing of the Group and a substantial reduction in the cost base and we are grateful for his leadership during this period.

 

We are now moving from a period of critical and significant change to one where we must take maximum advantage of the stronger platform that has been created. To achieve this, a different set of skills is required in the role of Chief Executive, in particular extensive knowledge and understanding of the defence markets in which we operate."

 

Michael Flowers has a beneficial shareholding of 80,680 Chemring shares.

 

There is no further information to be disclosed pursuant to paragraph 9.6.13R of the UK Listing Rules in relation to Michael Flowers' appointment as a director of Chemring.

 

Ends

 

 

 

 

For further information, contact:

 

Chemring Group PLC 01489 881 880

Peter Hickson, Chairman

Steve Bowers, Finance Director

Rupert Pittman, Group Director of Communications and Investor Relations

 

MHP Communications 020 3128 8100

Andrew Jaques

John Olsen

James White

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADDGDLSBDBGSX
Date   Source Headline
18th Dec 20241:30 pmRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 202410:30 amRNSDirector/PDMR Shareholding
18th Dec 20247:00 amRNSBlock listing Interim Review
17th Dec 202412:49 pmRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSResults for the year ended 31 October 2024
5th Dec 20247:00 amRNSDirectorate Change
2nd Dec 20247:00 amRNSTotal Voting Rights
14th Nov 20247:19 amRNSDirector Declaration
6th Nov 20247:15 amRNSDirector Declaration
4th Nov 20247:00 amRNS£278m Contract Wins
1st Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20247:00 amRNSTransaction in Own Shares
17th Oct 20247:00 amRNSTrading Update
14th Oct 202412:29 pmRNSHolding(s) in Company
1st Oct 20247:00 amRNSTotal Voting Rights
2nd Sep 20247:00 amRNSTotal Voting Rights
16th Aug 202410:10 amRNSAdditional Listing
5th Aug 202410:03 amRNSDirector/PDMR Shareholding
1st Aug 20247:00 amRNSTotal Voting Rights
18th Jul 20242:34 pmRNSDirector Declaration
1st Jul 20247:00 amRNSTotal Voting Rights
24th Jun 20247:00 amRNSAppointment of Chairman-designate
19th Jun 20247:00 amRNSBlock listing update
18th Jun 20247:00 amRNSBlock listing Interim Review
10th Jun 20247:00 amRNSContract Award
4th Jun 20247:00 amRNSHalf-year Report
3rd Jun 20247:00 amRNSTotal Voting Rights
1st May 202411:29 amRNSTotal Voting Rights
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20249:13 amRNSTotal Voting Rights
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSDirector/PDMR Shareholding
25th Mar 20247:00 amRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSFunding Awards
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.